Xvivo Perfusion AB
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.09 USD
2.72 M USD
87.88 M USD
24.74 M
About Xvivo Perfusion AB
Sector
Industry
CEO
Christoffer Rosenblad
Website
Headquarters
Gothenburg
Founded
1998
IPO date
Oct 8, 2012
Identifiers
2
ISIN SE0004840718
Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.
Related stocks
XVIVO Fibonacci levels and volume analysis for ConnyXVIVO Fibonacci levels and volume analysis.
Weekly chart
Simple short term analysis of XVIVO for Conny10 minute quick technical analysis on XVIVO.
Due to the monetary easing (Corona) and a 12 year bull market, the markets are over heated. The next correction will be brutal.
The equity markets in general seems like super high risk to me at the moment, but I trade crypto not equities so don't liste
Simple XVIVO long term analysis for ConnyChart is using Log scale (used for multi year analysis).
Respects the fib channel extremely well.
www.investopedia.com
Short
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
X026
Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistWeight
0.15%
Market value
368.16 K
USD
CEM
Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF EUR CWeight
0.15%
Market value
368.16 K
USD
WSCR
UBS (Irl) ETF plc - UBS MSCI World Small Cap Socially Responsible UCITS ETF USDWeight
0.03%
Market value
212.87 K
USD
UIMS
UBS (Irl) ETF plc - UBS MSCI World Small Cap Socially Responsible UCITS ETF Accum USDWeight
0.03%
Market value
212.87 K
USD
Explore more ETFs
Frequently Asked Questions
The current price of XVIPF is 23.52 USD — it has decreased by −2.61% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Xvivo Perfusion AB stocks are traded under the ticker XVIPF.
XVIPF stock has fallen by −2.61% compared to the previous week, the month change is a 16.00% rise, over the last year Xvivo Perfusion AB has showed a −45.83% decrease.
We've gathered analysts' opinions on Xvivo Perfusion AB future price: according to them, XVIPF price has a max estimate of 47.30 USD and a min estimate of 26.95 USD. Watch XVIPF chart and read a more detailed Xvivo Perfusion AB stock forecast: see what analysts think of Xvivo Perfusion AB and suggest that you do with its stocks.
XVIPF reached its all-time high on Aug 23, 2024 with the price of 52.38 USD, and its all-time low was 4.36 USD and was reached on Jul 8, 2015. View more price dynamics on XVIPF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
XVIPF stock is 2.68% volatile and has beta coefficient of 1.62. Track Xvivo Perfusion AB stock price on the chart and check out the list of the most volatile stocks — is Xvivo Perfusion AB there?
Today Xvivo Perfusion AB has the market capitalization of 648.23 M, it has decreased by −14.39% over the last week.
Yes, you can track Xvivo Perfusion AB financials in yearly and quarterly reports right on TradingView.
Xvivo Perfusion AB is going to release the next earnings report on Apr 24, 2026. Keep track of upcoming events with our Earnings Calendar.
XVIPF earnings for the last quarter are 0.11 USD per share, whereas the estimation was 0.07 USD resulting in a 52.77% surprise. The estimated earnings for the next quarter are 0.07 USD per share. See more details about Xvivo Perfusion AB earnings.
Xvivo Perfusion AB revenue for the last quarter amounts to 24.45 M USD, despite the estimated figure of 23.16 M USD. In the next quarter, revenue is expected to reach 25.83 M USD.
XVIPF net income for the last quarter is 3.42 M USD, while the quarter before that showed 459.61 K USD of net income which accounts for 645.08% change. Track more Xvivo Perfusion AB financial stats to get the full picture.
No, XVIPF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 14, 2026, the company has 198 employees. See our rating of the largest employees — is Xvivo Perfusion AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Xvivo Perfusion AB EBITDA is 17.66 M USD, and current EBITDA margin is 20.10%. See more stats in Xvivo Perfusion AB financial statements.
Like other stocks, XVIPF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Xvivo Perfusion AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Xvivo Perfusion AB technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Xvivo Perfusion AB stock shows the sell signal. See more of Xvivo Perfusion AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.